A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism

Low-molecular-weight heparin (LWMH) is recommended as the preferred anticoagulant treatment over vitamin K antagonists (VKA) for venous thromboembolism (VTE) in patients with cancer. However, there is uncertainty about the duration and dose of LMWH treatment. Therefore, we designed this multinationa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thrombosis and haemostasis 2013-11, Vol.110 (5), p.959-965
Hauptverfasser:	Kleinjan, Ankie, Aggarwal, Anita, Geer, Annemarie van de, Faselis, Charles, Büller, Harry R., Di Nisio, Marcello, Rickles, Frederick R., Kamphuisen, Pieter Willem
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticoagulant treatment Anticoagulants - therapeutic use Biological and medical sciences Blood Coagulation, Fibrinolysis and Cellular Haemostasis Blood coagulation. Blood cells Data Collection Drug Dosage Calculations Europe Fundamental and applied biological sciences. Psychology Hematologic and hematopoietic diseases Hematology - statistics & numerical data Heparin, Low-Molecular-Weight - therapeutic use Humans malignancy Medical Oncology - statistics & numerical data Medical sciences Molecular and cellular biology Neoplasms - complications Neoplasms - drug therapy Platelet diseases and coagulopathies Time Factors United States Venous Thromboembolism - complications Venous Thromboembolism - drug therapy Venous thrombosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!